|2.||Hodgkin Disease (Hodgkin's Disease)
|3.||Head and Neck Neoplasms (Head and Neck Cancer)
|5.||Esophageal Neoplasms (Esophageal Cancer)
|1.||Schneider, Uwe: 12 articles (08/2015 - 11/2002)|
|2.||Newhauser, Wayne D: 10 articles (05/2015 - 04/2009)|
|3.||Paganetti, Harald: 8 articles (01/2016 - 07/2008)|
|4.||Zhang, Rui: 7 articles (05/2015 - 12/2010)|
|5.||Curtis, Rochelle E: 7 articles (01/2014 - 06/2005)|
|6.||Robison, Leslie L: 6 articles (11/2015 - 06/2002)|
|7.||Howell, Rebecca M: 5 articles (05/2015 - 11/2012)|
|8.||Taddei, Phillip J: 5 articles (10/2014 - 04/2009)|
|9.||Yock, Torunn I: 5 articles (06/2014 - 10/2012)|
|10.||Tarbell, Nancy J: 5 articles (01/2014 - 09/2002)|
09/15/1997 - "Retinoids are useful in the treatment of premalignant oral lesions and in preventing the occurrence of second primary cancers after resection of the initial primary oral cancer, but long-term prognosis is still poor, presumably due to malignant cells escaping retinoid control. "
03/01/2001 - "Likewise, retinoids prevent the development of second primary cancers in head and neck and lung cancer patients who had been treated for the first primary. "
01/01/2001 - "Retinoids reverse potentially malignant lesions and inhibit the development of second primary cancers in patients with head-and-neck cancer. "
09/01/1997 - "Likewise, retinoids prevent the development of second primary cancers in head and neck and lung cancer patients who had been treated for the first primary. "
07/01/1996 - "Likewise, retinoids prevent the development of second primary cancers in head/neck and lung cancer patients who had been treated for the first primary. "
|2.||lenalidomide (CC 5013)FDA Link
05/10/2012 - "Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). "
09/01/2014 - "An increased incidence of second primary cancers was observed in the lenalidomide group (RR 2.61 [1.60, 4.27], p < 0.001). "
03/01/2014 - "Lenalidomide and second malignancies in myeloma patients."
06/01/2012 - "Although recent reports have suggested an increased rate of second cancers in myeloma patients treated with lenalidomide, the true impact of this agent and other novel anti-myeloma therapies on the incidence of additional malignancies remains to be clarified."
05/10/2012 - "Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). "
09/01/2013 - "The objective of this study was to compare the incidence of second cancers in patients treated with proton radiation with a population-based cohort of matched patients treated with photon radiation. "
01/01/2011 - "This study compared 6-MV IMRT and proton therapy in terms of organ specific second cancer lifetime attributable risks (LARs) caused by scattered and secondary out-of-field radiation. "
04/21/2009 - "The aims of this study were to calculate doses to major organs and tissues and to estimate second cancer risk from stray radiation following craniospinal irradiation (CSI) with proton therapy. "
05/21/2015 - "Proton therapy confers substantially lower predicted risk of second cancer compared with photon therapy. "
05/21/2015 - "Risk-optimized proton therapy to minimize radiogenic second cancers."
|4.||Etoposide (VP 16)FDA LinkGeneric
05/01/2010 - "The current treatments with etoposide or carboplatine expose the patient to the late risk of second cancer. "
06/01/2005 - "Two cases developed second malignancies secondary to etoposide. "
11/01/2001 - "High-dose therapy, and less markedly, etoposide, may contribute to the overall second cancer risk."
02/01/2010 - "Decreased use of etoposide and cranial irradiation likely contributed to the low incidence of second cancers. "
01/01/2003 - "There was no overall long term reduction in second cancers beyond 10 years in stage 1 patients after orchidectomy alone compared to stage 1 or metastatic disease patients receiving chemotherapy though the incidence was non significantly lower up to 10 years particularly in those patients receiving etoposide based combination. "
05/03/1995 - "In the Stockholm Trial, there was a statistically significant (P = .008) reduction in the incidence of second primary cancers in the contralateral breast among the tamoxifen-treated patients. "
10/01/2008 - "Given the widespread use of tamoxifen there is considerable interest in elucidating the mechanisms underlying treatment-associated cancer. "
01/01/2006 - "Histological examination of the endometrium, done based on the suspicion of a second primary cancer due to the tamoxifen therapy, revealed a granulomatous reaction. "
03/01/2001 - "Our data also suggest that tamoxifen does not increase the risk of other second primary cancers. "
12/01/2000 - "The incidence and risk of second primary cancers associated with tamoxifen therapy is low. "
|6.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/01/1995 - "The combination of cyclophosphamide with irradiation has had unequivocal success in reconstituting a sustained engraftment, but this procedure has severe associated risks such as second malignancies. "
04/05/1995 - "Evaluations of the risk of second cancer as a result of treatment with cyclophosphamide alone, radiation alone, or both therapies were made relative to those patients who were exposed to neither treatment modality. "
03/01/1991 - "Longer term complications of cyclophosphamide therapy include infertility and an increased incidence of second malignancies. "
05/01/1986 - "The results also suggest that the use of cyclophosphamide may increase the risk of second primary neoplasms in patients with genetic retinoblastoma. "
04/01/2005 - "Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma."
02/01/1993 - "Despite the small number of cases and potential confounding by other agents, these findings, together with those of previous studies, suggest that some non-alkylating agents may predispose to second malignancies."
05/01/1985 - "This finding may be compatible with the clinical observation that the vast majority of patients with second malignancy are found in the group treated with alkylating agents. "
01/01/2011 - "Additionally, it will review how second malignancies have changed with the shift in treatment from high-dose radiation to chemotherapy regimens including alkylators and epipodophyllotoxins. "
08/01/2001 - "The risk factors for these complications did not differ from those in previous reports and included alkylating agents and/or radiotherapy for second neoplasms and anthracycline therapy and radiotherapy for cardiac toxicity. "
10/01/2000 - "The risk factors for this complications did not differ to previous reports and included alkylating agents and/or radiotherapy for second neoplasms and anthracycline therapy and radiotherapy for cardiac toxicity. "
|8.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/01/2004 - "At a mean follow-up of about 18 years (10-30 years), 177 patients (44.0%) remained continuously free of disease, 2 died of doxorubicin-induced cardiotoxicity and 8 developed a second neoplasm (5 died, and 3 are alive and free of disease). "
09/01/1997 - "At a mean follow-up of 14.8 years, with the 95% of patients with a minimum FU of 10 years, 101 pts (40%) remained continuously free of disease, 144 patients relapsed, two patients died of adriamycin cardiotoxicity and 5 patients developed a second neoplasm. "
03/01/1995 - "Second malignancies associated with doxorubicin."
01/01/1996 - "Lower cumulative exposure to alkylating agents, doxorubicin, bleomycin and limited use of radiation is expected to improved the prospects for fertility and decrease the risks for second neoplasms and late cardiopulmonary toxicity."
05/01/2001 - "In prior studies, it was demonstrated that the redox metabolism of doxorubicin leads to the formation of promutagenic oxidized DNA bases in human chromatin, suggesting a potential mechanism for doxorubicin-related second malignancies. "
|9.||Melphalan (Alkeran)FDA LinkGeneric
01/01/1986 - "Chromosome damage and second malignancy in patients treated with melphalan."
02/01/2013 - "Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma."
03/01/1984 - "Alkylating agents such as melphalan, chlorambucil and cyclophosphamide seem to lead to the highest rate of second malignancies. "
07/01/2000 - "Comparing MOPPEBVCAD vs. MOPPEBVCyED, the results were as follows: complete remissions 35/35 vs. 30/32 (plus one partial remission and one disease progression); relapses 5 vs. 8; deaths 2 (one of myelodysplasia) vs. 2; delivered mean dose intensity (DI): lomustine 0.79+/-0.67 vs. cyclophosphamide 0.82+/-0.32; melphalan 0.80+/-0.13 vs. etoposide 0.86+/-0.18; average DI of the 7 drugs common to both regimens 0.73+/-0.10 vs. 0.83+/-0.11; all 9 drugs 0.75+/-0.13 vs. 0.84+/-0.09 (p=0.002); projected 5-year failure-free survival 0.79 vs 0.62; second cancers, two myelodysplasias vs. one carcinoma of the kidney. "
01/01/2013 - "The aim of the study was to determine the incidence of second malignancies among patients with Hodgkin lymphoma (HL) treated with autologous haematopoietic stem cell transplantation (ASCT) following a modified BEAM (BCNU, etoposide, cytarabine, melphalan, dexamethasone) regimen between 1992 and 2012 at our department. "
|10.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
10/20/2005 - "This study evaluated prospectively the value of integrated whole-body positron emission tomography and computed tomography (PET/CT) using [18F] fluorodeoxyglucose (FDG) in detecting a second primary cancer at the time of the initial staging in comparison with a conventional staging work-up (CSW). "
08/01/2006 - "In 4/11 patients, 18FDG PET revealed an unsuspected second neoplasm in addition to MCC. "
10/20/2005 - "Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging."
04/01/2014 - "Lymphoma as a second malignancy in a patient with neuroendocrine tumor: mimicking dedifferentiation on dual-tracer PET/CT with 68Ga-DOTANOC and 18F-FDG."
|1.||Drug Therapy (Chemotherapy)
01/17/2005 - "Greater awareness of the late effects of chemotherapy has led to changes in the treatment protocols for ALL, with improvement in neurocognitive outcomes and reduced rates of second malignancies. "
06/15/2001 - "Events were as follows: progression during therapy, n = 2; progression or relapse after therapy, n = 20; second malignancy, n = 1. It was concluded that short-pulse chemotherapy, stratified according to stage, is effective treatment for pediatric ALCL. "
04/01/1988 - "CMT resulted in an approximate 20% improvement in survival with no increase in second malignancies when compared with chemotherapy alone."
08/01/2008 - "In this study, we retrospectively investigated long-term development of hematological and non-hematological second malignancies in 331 patients with ET, analyzing possible associations with chemotherapy treatments. "
05/01/1991 - "These qualifications not withstanding, most studies implicate central nervous system radiation with and without chemotherapy as the primary etiology for second malignancies."
10/01/2007 - "Second malignancies are an uncommon but serious sequela of radiotherapy, with potential for significant health problems in patients with complete remission of primary disease. "
05/20/2015 - "This study investigated the long-term probability of developing a second cancer in a large pooled cohort of patients treated with surgery with or without radiotherapy (RT). "
11/01/2013 - "The purpose of this study was to measure the scattered dose to out-of-field organs from head and neck radiotherapy in pediatric patients and to estimate the risk for second cancer induction to individual organs. "
12/01/2012 - "This study was conducted to estimate the scattered thyroid dose and relevant second cancer risk from radiotherapy for extracranial tumours during childhood. "
01/01/2011 - "This study indicated an increased relative risk of all second cancers combined following radiotherapy (1.22, 95% CI: 0.88 to 1.69). "
07/01/1992 - "At a median follow-up of 9 years 43% of the patients with localized disease, treated with adjuvant and neo-adjuvant chemotherapy remained continuously disease free, 53% developed metastatic disease and/or local recurrences and 2% had a second malignancy. "
03/01/2012 - "Independent of adjuvant chemotherapy or radiation, stage of disease, comprehensive surgical staging, and the presence of a second malignancy were predictors of overall survival."
08/01/2008 - "As a result, adjuvant chemotherapy using 5-fluorouracil(Tegafur)did was not cause second malignancy under multivariate analysis. "
08/01/2008 - "In 1999, Fujimoto mentioned that adjuvant chemotherapy and chemo-immune-therapy cause a second malignancy. "
12/01/1999 - "There are few indications of modification of radiation-associated second cancer relative risk among those treated with adjuvant chemotherapy, nor are there strong indications of modification of radiation-associated relative risk by heritable genetic factors. "
11/01/1995 - "Among those cured of the disease by orchiectomy and postoperative irradiation, there is a risk of having a second malignancy. "
02/01/2013 - "The uncertainties about differences in relapse and rates of other late events such as second malignancy and cardiovascular events for the three post-orchidectomy strategies in seminoma stage I patients has led to debates about whether the three strategies are equally effective and safe. "
08/01/2012 - "The uncertainties about differences in relapse and rates of other late events such as second malignancy and cardiovascular events for the three post-orchidectomy strategies in seminoma stage I patients has led to debates about whether the three strategies are equally effective and safe. "
10/01/2003 - "We report a case of a 50-year-old man with two synchronous second malignancies 25 years after orchiectomy and adjuvant radiotherapy for seminoma. "
01/01/2010 - "We report coexistence of prostate cancer and testicular liposarcoma in a 69 year-old-man because while orchiectomy endications are decreasing day by day, these second malignancies should not be missed."
06/01/1996 - "Chemoprevention studies might target those at risk for recurrence or a second neoplasm."
11/01/2006 - "Although chemoprevention of second cancers has been realized, it has become increasingly apparent that not all benefit equally. "
11/01/2006 - "Chemoprevention of second cancers."
04/27/2002 - "With breast-conserving therapy, chemoprophylaxis or other interventions to reduce the rate of second cancers may be valuable. "
11/01/1994 - "The problem of second cancers and the European experience with chemoprevention."